Evoke Pharma Gross Margin 2012-2024 | EVOK
Current and historical gross margin for Evoke Pharma (EVOK) over the last 10 years. The current gross profit margin for Evoke Pharma as of September 30, 2024 is %.
| Evoke Pharma Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2024-06-30 |
$0.01B |
$0.01B |
100.00% |
| 2024-03-31 |
$0.01B |
$0.01B |
100.00% |
| 2023-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2023-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2023-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2023-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2022-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2022-09-30 |
$0.00B |
$0.00B |
100.00% |
| 2022-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2022-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2021-12-31 |
$0.00B |
$0.00B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.008B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
